Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by BidaskClub to “Buy”

BidaskClub upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, BidAskClub reports.

Other equities research analysts have also recently issued reports about the company. Jefferies Financial Group set a $46.00 price objective on Supernus Pharmaceuticals and gave the company a buy rating in a research note on Friday, August 30th. Mizuho reaffirmed a buy rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, August 7th. Stifel Nicolaus set a $55.00 price objective on Supernus Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 7th. Cowen set a $50.00 price objective on Supernus Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 7th. Finally, TheStreet cut Supernus Pharmaceuticals from a b- rating to a c+ rating in a research note on Thursday, August 29th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. Supernus Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $53.38.

NASDAQ:SUPN traded down $0.33 on Thursday, reaching $27.56. The company’s stock had a trading volume of 28,418 shares, compared to its average volume of 484,017. Supernus Pharmaceuticals has a 12-month low of $25.32 and a 12-month high of $51.38. The company has a quick ratio of 2.53, a current ratio of 2.72 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of 13.46, a price-to-earnings-growth ratio of 0.98 and a beta of 1.62. The stock has a 50 day moving average price of $28.86 and a 200 day moving average price of $33.29.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.05. Supernus Pharmaceuticals had a return on equity of 22.36% and a net margin of 25.66%. The business had revenue of $104.70 million during the quarter, compared to analysts’ expectations of $109.67 million. During the same period in the previous year, the firm posted $0.57 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. Equities research analysts expect that Supernus Pharmaceuticals will post 2.16 EPS for the current fiscal year.

In other news, CEO Jack A. Khattar acquired 7,200 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $26.39 per share, with a total value of $190,008.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.57% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SUPN. Rice Hall James & Associates LLC grew its stake in Supernus Pharmaceuticals by 35.1% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,351,286 shares of the specialty pharmaceutical company’s stock worth $44,714,000 after purchasing an additional 350,905 shares in the last quarter. Nuveen Asset Management LLC grew its stake in Supernus Pharmaceuticals by 2,491.0% during the 2nd quarter. Nuveen Asset Management LLC now owns 310,612 shares of the specialty pharmaceutical company’s stock worth $10,278,000 after purchasing an additional 298,624 shares in the last quarter. Marshall Wace North America L.P. grew its stake in Supernus Pharmaceuticals by 121.7% during the 2nd quarter. Marshall Wace North America L.P. now owns 501,783 shares of the specialty pharmaceutical company’s stock worth $16,605,000 after purchasing an additional 275,490 shares in the last quarter. Marshall Wace LLP grew its stake in Supernus Pharmaceuticals by 49.2% during the 1st quarter. Marshall Wace LLP now owns 632,730 shares of the specialty pharmaceutical company’s stock worth $22,171,000 after purchasing an additional 208,766 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Supernus Pharmaceuticals by 30.7% during the 2nd quarter. Renaissance Technologies LLC now owns 604,200 shares of the specialty pharmaceutical company’s stock worth $19,993,000 after purchasing an additional 141,900 shares in the last quarter. 99.35% of the stock is owned by hedge funds and other institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

See Also: Why are trading ranges significant?

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit